EVE Health Group Limited (ASX:EVE)

Australia · Delayed Price · Currency is AUD

0.0150

0.00 (0.00%)

Sep 4, 2026, 10:27 AM AEST

-51.61% (1Y)

Market Cap	5.28M -30.8%
Revenue (ttm)	1.15M -33.5%
Net Income	-1.89M
EPS	-0.01
Shares Out	352.33M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	75,000
Open	0.0150
Previous Close	0.0150
Day's Range	0.0150 - 0.0150
52-Week Range	0.0140 - 0.0360
Beta	0.46
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 4, 2026

About EVE Health Group

EVE Health Group Limited, together with its subsidiaries, engages in the development, retail, and commercialization of health and wellness, and pharmaceutical products. The company lead product is Dyspro, a proprietary pharmaceutical-grade formulation to address dysmenorrhea (menstrual pain); and Libbo, a proprietary pharmaceutical-grade oral dissolving film formulation for the treatment of erectile dysfunction. It also offers Lactobacillus rhamnosus Beebiotic MAP01, a proprietary strain to support digestive health and vitality. The company was... [Read more]

Industry Packaged Foods

Sector Consumer Staples

Founded 2003

Country Australia

Stock Exchange Australian Securities Exchange

Ticker Symbol EVE

Full Company Profile

Financial Performance

In fiscal year 2026, EVE Health Group's revenue was 1.15 million, a decrease of -33.53% compared to the previous year's 1.73 million. Losses were -1.89 million, 19.7% more than in 2025.

Financial Statements